Last reviewed · How we verify

Zinc deficiency — Treatment Landscape & Competitive Intelligence

Zinc deficiency (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Zinc deficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zinc Sulfate ZINC SULFATE Am Regent zinc sulfate 1987-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Zinc deficiency
  2. Am Regent · 1 drug in Zinc deficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Zinc deficiency:

Cite this brief

Drug Landscape (2026). Zinc deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/zinc-deficiency. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing